Company Overview and News


Add ALNY
to your dashboard

Headline News

Prothena (PRTA) Tumbles 18% in a Year: What Lies Ahead?

2018-01-15 zacks
Shares of Prothena Corporation (PRTA - Free Report) lost 18.1% over a year as against the industry’ gain of 3.1%. (61-0)

Stocks To Watch: Guidance Updates All Around

2018-01-13 seekingalpha
Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. (668-7)

When The Bulls Growl And The Bears Moo - Stock Market Outlook 2018

2018-01-10 seekingalpha
Stocks remain in a major uptrend. Staying the course worked great in 2017 and remains an effective strategy even now. (701-4)

Your Daily Pharma Scoop: Ablynx Takeover Bid, Celgene Acquires Impact Biomedicines, Axovant Flops Again

2018-01-09 seekingalpha
Today we will discuss the hostile takeover bid from Novo Nordisk (NVO) for clinical-stage Belgian biotech company Ablynx (OTCPK:ABLYF). (411-5)

Achillion Pharmaceuticals: Ultra-Rare Disease Company With Ultra-Rare Enterprise Value

2018-01-09 seekingalpha
Achillion (ACHN) is a biopharmaceutical company specializing in discovering and developing small molecules for complement-mediated diseases. (303-2)

Regeneron, Sanofi Expand Investment in Cemiplimab & Dupilumab

2018-01-09 zacks
Regeneron Pharmaceuticals, Inc. (REGN - Free Report) and partner Sanofi (SNY - Free Report) announced that they will expand their investment for the development of the programmed cell death protein 1 (PD-1) antibody, cemiplimab, in oncology and label expansion of the IL-4/IL-13 pathway-blocking antibody, dupilumab, in Type II allergic diseases. (45-0)

Alnylam, Sanofi Announce Restructuring Deal for RNAi Products

2018-01-08 zacks
Alnylam Pharmaceuticals, Inc. (ALNY - Free Report) and Sanofi (SNY - Free Report)  announced a strategic restructuring of their RNAi therapeutics rare genetic diseases alliance. The companies entered into the agreement to optimize the development and commercialization of certain products for the treatment of rare genetic diseases. (52-0)

Regeneron forms consortium to accelerate gene sequencing project - Channel NewsAsia

2018-01-08 channelnewsasia
REUTERS: Regeneron Pharmaceuticals Inc on Monday announced a collaboration with rival drugmakers that will speed its effort to collect genetic information on 500,000 people in the UK Biobank database, a project it believes could help accelerate new drug discovery and improve approval success rates. (147-0)

Regeneron forms consortium to accelerate gene sequencing project

2018-01-08 reuters
(Reuters) - Regeneron Pharmaceuticals Inc on Monday announced a collaboration with rival drugmakers that will speed its effort to collect genetic information on 500,000 people in the UK Biobank database, a project it believes could help accelerate new drug discovery and improve approval success rates. (147-0)

Rivals Help Fund Regeneron’s Gene-Sequencing Effort - WSJ

2018-01-08 wsj
Some of the world’s largest pharmaceutical companies are pooling resources to fund an ambitious genetic and medical database aimed at bolstering the search for new drugs. (200-0)

Sanofi to market new hemophilia drug in deal with Alnylam - Channel NewsAsia

2018-01-08 channelnewsasia
French pharmaceutical group Sanofi said it has obtained the right to develop and sell a new hemophilia drug in a restructuring of its partnership with U.S. Alnylam Pharmaceuticals. (17-0)

Sanofi to market new hemophilia drug in deal with Alnylam

2018-01-08 reuters
PARIS (Reuters) - French pharmaceutical group Sanofi said it has obtained the right to develop and sell a new hemophilia drug in a restructuring of its partnership with U.S. Alnylam Pharmaceuticals. (17-0)

Zach Hartman, PhD Positions For 2018: Oncology And Immunotherapy In Focus

2017-12-31 seekingalpha
Cell therapy is going to be a big factor in 2018, with companies like Gilead and Juno Therapeutics leading the charge. (50-0)

Top 10 Biopharma Events Kicking Off 2018

2017-12-28 247wallst
Biotechnology and pharmaceutical companies generally face a fair-to-great amount of risk based on the lengthy vetting process for their drug candidates, should a study come back negative or should a candidate not be approved. On the other hand, if a drug is approved or passes a clinical trial, there can be massive upside. (400-2)

CUSIP: 02043Q107